Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
Portfolio Pulse from Benzinga Insights
Analysts have mixed opinions on Regenxbio (NASDAQ:RGNX), with recent ratings ranging from bullish to indifferent. The average 12-month price target is $31.5, down from $34.00, with high and low estimates of $45.00 and $21.00 respectively. Regenxbio's financials show challenges in revenue growth and efficiency, with a significant revenue decline and below-average ROE and ROA, despite a strong net margin and low debt-to-equity ratio.
March 06, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regenxbio faces mixed analyst opinions, with a downward revision in the average price target. Financial challenges include a significant revenue decline and below-average ROE and ROA, despite a strong net margin.
The mixed analyst ratings and the downward revision in the average price target suggest uncertainty about Regenxbio's future performance. However, the company's strong net margin and low debt-to-equity ratio may provide some stability. The significant revenue decline and below-average ROE and ROA indicate challenges in growth and efficiency, which could impact investor sentiment in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100